이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Study of SYH2053 Injection in Participants With Renal Impairment Compared to Participants With Normal Renal Function

A Phase I Clinical Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of SYH2053 Injection in Participants With Normal Renal Function and Renal Impairment: A Non-randomized, Open-label, Parallel-Controlled, Single-Dose Study

This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of SYH2053 injection in participants with moderate, and severe renal impairment compared to participants with normal renal function.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

24

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Clinical Trials Information Group officer
  • 전화번호: 0311-69085587
  • 이메일: ctr-contact@cspc.cn

연구 장소

    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100191
        • 모병
        • Peking University Third Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Aged between 18 and 75 years (inclusive) at the time of screening, males or females.
  • Body weight ≥ 45.0 kg for females or ≥ 50.0 kg for males, and body mass index (BMI) between 18.0 and 35.0 kg/m² (inclusive), where BMI = weight (kg) / height² (m²).
  • LDL-C ≥ 70 mg/dL (1.8 mmol/L) at the screening visit.
  • Participants of childbearing potential, as well as their partners, must agree to use effective and reliable contraceptive measures from the signing of the informed consent form until at least 6 months after study drug administration.
  • Participants must be able to communicate well with the investigator and be willing and able to comply with all protocol requirements throughout the study.
  • For participants with renal impairment: if lipid-lowering agents (including statins, ezetimibe, fibrates, etc.) have been used prior to screening, the dose must have been stable for at least 4 weeks, or the agent must have been discontinued for at least 2 weeks. During the study period, the dose and frequency of previous lipid-lowering therapy are planned to remain unchanged.
  • For participants with renal impairment: participants must have stable renal function, and the eGFR must meet the corresponding renal function classification criteria for the respective group, i.e.: Moderate renal impairment: 30 mL/min ≤ eGFR < 60 mL/min; Severe renal impairment: 15 mL/min ≤ eGFR < 30 mL/min
  • For participants with renal impairment: physical examination, vital signs, laboratory tests, 12-lead ECG, chest X-ray, abdominal ultrasound, and other examination results must be judged by the investigator as suitable for participation in this study.
  • For participants with normal renal function: no use of any medication (including over-the-counter supplements and vitamins) within 4 weeks prior to screening.
  • For participants with normal renal function: 90 mL/min ≤ eGFR < 130 mL/min.
  • For participants with normal renal function: physical examination, vital signs, laboratory tests, 12-lead ECG, chest X-ray, abdominal ultrasound, and other examination results must be normal or show abnormalities without clinical significance.

Exclusion Criteria:

  • History of severe allergic diseases, such as anaphylactic shock, systemic severe urticaria, etc., or a history of allergy to oligonucleotide drugs.

  • Any of the following cardiovascular or cerebrovascular events within 6 months prior to screening: unstable angina, myocardial infarction, transient ischemic attack or cerebrovascular accident (e.g., stroke), coronary artery bypass grafting; or other cardiovascular and cerebrovascular diseases that, in the investigator's assessment, make the participant unsuitable for participation in this clinical trial.

  • Prolonged Fridericia-corrected QT interval (QTcF) on a 12-lead electrocardiogram at screening (QTcF: >450 ms for males, >470 ms for females); or severe cardiac arrhythmias (e.g., recurrent or symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia) that, in the investigator's assessment, make the participant unsuitable for participation in this clinical trial.

  • Prior surgery that may affect drug distribution, metabolism, or excretion (e.g., liver or kidney surgery), or anticipated hospitalization during the study period due to surgery or other reasons.

  • Meeting any of the following at screening:

    1. For participants with renal impairment: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; for participants with normal renal function: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg;
    2. Triglycerides >5.7 mmol/L.
  • For participants with renal impairment: alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma-glutamyl transferase (GGT) >2.5 × upper limit of normal (ULN), or total bilirubin >2 × ULN; for participants with normal renal function: ALT, AST, GGT, or total bilirubin >1.5 × ULN.

  • Diagnosis of malignancy within 5 years prior to screening (except for adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, cervical carcinoma in situ, and ductal carcinoma in situ of the breast).

  • Use of PCSK9 monoclonal antibody drugs or oral PCSK9 inhibitors within 180 days prior to screening; use of Leqvio® or any other RNA-based therapy for lipid-lowering purposes within 2 years prior to screening, including but not limited to siRNA or antisense oligonucleotide therapy.

  • Participation in another clinical trial within 3 months prior to screening (i.e., less than 3 months since the last dose of the investigational product).

  • Average daily smoking of more than 5 cigarettes (or equivalent tobacco in e-cigarettes) within 3 months prior to screening, and/or unwillingness to refrain from using any tobacco products during the study period.

  • Regular alcohol consumption within 6 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 360 mL of beer with 5% alcohol content, or 45 mL of spirits with 40% alcohol content, or 150 mL of wine with 12% alcohol content), and/or inability to abstain from alcohol during the study period, and/or a positive breath alcohol test.

  • History of drug abuse, and/or a positive urine drug screening test.

  • Regular consumption of caffeine exceeding 600 mg per day within 3 months prior to screening (1 cup of coffee contains approximately 100 mg of caffeine, 1 cup of tea contains approximately 30 mg of caffeine, and 1 can of cola contains approximately 20 mg of caffeine), or planned use of caffeine-containing products or medications within 24 hours prior to study drug administration.

  • Blood loss or blood donation exceeding 400 mL within 3 months prior to dosing, and/or platelet donation within 2 weeks prior to dosing.

  • Pregnant or lactating women; female participants of childbearing potential with a serum pregnancy test result exceeding the upper limit of normal at screening; or female participants who had unprotected sexual intercourse within 2 weeks prior to screening.

  • For participants with normal renal function: positive for any of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or Treponema pallidum antibody; for participants with renal impairment: positive for HBsAg with detectable HBV-DNA, positive for HCV antibody with detectable HCV-RNA, positive for HIV antibody, or positive for Treponema pallidum antibody, meeting any of the above criteria.

  • Currently receiving renal replacement therapy (including kidney transplantation, hemodialysis, etc.).

  • Presence of urinary incontinence at screening.

  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for participation in this clinical trial.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: SYH2053(normal renal function)

Participants will receive a single dose of SYH2053 administered by SC injection on Day 1. Normal renal function is defined as estimate glomerular filtration rate (eGFR) of ≥90 milliliter (mL)/minute (min) and <130 mL/min.

subcutaneous injection

실험적: SYH2053(moderate renal function)

Participants will receive a single dose of SYH2053 administered by SC injection on Day 1. Moderate renal function is defined as eGFR of ≥30 mL/min and <60 mL/min.

subcutaneous injection

실험적: SYH2053(severe renal function)

Participants will receive a single dose of SYH2053 administered by SC injection on Day 1. Severe renal function is defined as eGFR of ≥15 mL/min and <30 mL/min.

subcutaneous injection

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Maximum observed plasma concentration (Cmax)
기간: Time Frame: Pre-dose and multiple timepoints up to 4 days
Time Frame: Pre-dose and multiple timepoints up to 4 days
Area under the curve of the plasma concentration (AUC)
기간: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Time to reach maximum plasma concentration (Tmax)
기간: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Terminal half-life (t1/2)
기간: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Apparent total clearance (CL/F)
기간: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Apparent volume of distribution (Vz/F)
기간: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Amount excreted unchanged in urine (Ae) of SYH2053 over 72 hours post-dose
기간: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Fraction excreted (fe) of SYH2053 over 72 hours post-dose
기간: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Renal clearance (CLr) of SYH2053
기간: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
The serum Low-density lipoprotein cholesterol (LDL-C) level
기간: through study completion, an average of 6 months
through study completion, an average of 6 months
The serum PCSK9 level
기간: through study completion, an average of 6 months
through study completion, an average of 6 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 7월 15일

기본 완료 (추정된)

2027년 7월 15일

연구 완료 (추정된)

2027년 9월 15일

연구 등록 날짜

최초 제출

2026년 7월 2일

QC 기준을 충족하는 최초 제출

2026년 11월 11일

처음 게시됨 (실제)

2026년 11월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다